# US 2022/0031708 A1 · Method for treating idiopathic pulmonary fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031708 A1
- Document ID: US20220031708A1
- Status: Published application
- Kind: A1
- Application number: 17/376,311
- Filed: 2021-07-15
- Published: 2022-02-03
- Earliest claimed: 2019-01-25
- Assignees: Numedii, Inc.
- Applicants: NuMedii, Inc.
- Inventors: Asim Siddiqui; Heather Arnett; Linda De Young; Tarangini Deshpande
- Web page: https://patentgrep.com/patent/US20220031708A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 11/00: Drugs for disorders of the respiratory system
- C12N 5/0688: {Cells from the lungs or the respiratory tract}
- C12N 2501/727: Kinases (EC 2.7.)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a method of treating idiopathic pulmonary fibrosis (IPF) using an agent that reduces or eliminates the kinase activity of checkpoint kinase 1 (Chk1).

## Claims

### Claim at position 1

1-62. (canceled)

### Claim 63

A method of treating pulmonary fibrosis in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a Chk1 inhibitor, wherein upon the administering, the Chk1 inhibitor reduces a level of fibroblast to myofibroblast differentiation in the subject by at least about 5% relative to a control.

### Claim 64 (depends on 63)

The method of claim 63, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

### Claim 65 (depends on 63)

The method of claim 63, wherein the control is a level of fibroblast to myofibroblast differentiation in a control subject that was not administered the Chk1 inhibitor.

### Claim 66 (depends on 63)

The method of claim 63, wherein the control is a level of fibroblast to myofibroblast differentiation in the subject prior to the administering the Chk1 inhibitor.

### Claim 67 (depends on 63)

The method of claim 63, wherein the level of fibroblast to myofibroblast differentiation is as determined by contacting fibroblasts with TGF-β, staining the fibroblasts with a reagent that specifically stains alpha smooth muscle actin, and conducting high content analysis to determine percent inhibition of alpha smooth muscle actin induction.

### Claim 68 (depends on 63)

The method of claim 63, wherein the Chk1 inhibitor is not a thiazole compound, a heterocyclic urea compound, a heterocyclic thiourea compound, or an anilinopiperazine compound.

### Claim 69 (depends on 63)

The method of claim 63, wherein the Chk1 inhibitor is CCT-245737.

### Claim 70 (depends on 63)

The method of claim 63, wherein the subject is a mammal.

### Claim 71 (depends on 63)

The method of claim 63, wherein the subject is a human.

### Claim 72 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered in a unit dosage form.

### Claim 73 (depends on 63)

The method of claim 63, further comprising administering an additional therapeutic agent to the subject.

### Claim 74 (depends on 73)

The method of claim 73, wherein the additional therapeutic agent comprises nintedanib.

### Claim 75 (depends on 73)

The method of claim 73, wherein the additional therapeutic agent comprises pirfenidone.

### Claim 76 (depends on 73)

The method of claim 73, wherein the additional therapeutic agent comprises an immunomodulatory agent.

### Claim 77 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered via inhalation.

### Claim 78 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered orally.

### Claim 79 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered parenterally.

### Claim 80 (depends on 63)

The method of claim 63, wherein the therapeutically-effective amount is from about 0.1 μg/kg to about 100 mg/kg.

### Claim 81

A method of reducing differentiation of a fibroblast into a myofibroblast, comprising contacting a population of cells with a Chk1 inhibitor, wherein the population of cells comprises the fibroblast, wherein upon contacting the population of cells with the Chk1 inhibitor, the fibroblast exhibits an expression level of alpha smooth muscle actin that is at least about 5% lower than an expression level of the alpha smooth muscle actin by a fibroblast that was not contacted with the Chk1 inhibitor.

### Claim 82

A method of reducing collagen deposition, comprising contacting a tissue with a Chk1 inhibitor, wherein upon contacting the tissue with the Chk1 inhibitor, the tissue exhibits an at least about 5% lower level of an indicator of collagen deposition relative to a tissue that was not contacted with the Chk1 inhibitor.
